Cancer Stem Cell News Volume 9.30 | Aug 12 2020

May 12, 2022

304

2020-08-12 | CSCN 9.30

Cancer Stem Cell News by STEMCELL Technologies

Vol. 9.30 – 12 August, 2020

TOP STORY

PAF1
Regulates Stem Cell Features of Pancreatic Cancer Cells, Independently of the PAF1 Complex, via Interactions with PHF5A and DDX3

Researchers investigated mechanisms by which PAF1 maintains cancer stem cells and contributes to development of pancreatic tumors.
[Gastroenterology]

Abstract Graphical Abstract

Watch 'collaborating to accelerate COVID-19 research'

PUBLICATIONSRanked by the impact factor of the journal

Serial
Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy

Scientists examined the prognostic significance of circulating tumor cell dynamics during treatment in metastatic breast cancer patients receiving first-line chemotherapy.
[JNCI-Journal of the National Cancer institute]

Abstract

LC3B
Upregulation by NANOG Promotes Immune Resistance and Stem-Like Property through Hyperactivation of EGFR Signaling in Immune-Refractory Tumor Cells

The authors report that the emergence of refractory phenotypes was highly associated with an aberrant macroautophagic/autophagic state of NANOG⁺ tumor cells and that the autophagic phenotype arose through transcriptional induction of MAP1LC3B/LC3B by NANOG.
[Autophagy]

Abstract

Broccoli
Extract Increases Drug-Mediated Cytotoxicity towards Cancer Stem Cells of Head and Neck Squamous Cell Carcinoma

Researchers investigated whether sulforaphane could enhance the chemotherapeutic effects of cisplatin and 5-fluorouracil against head and neck squamous cell carcinomas–cancer stem cells, and its mechanisms of action.
[British Journal of Cancer]

Abstract

EGFR/FOXO3a/BIM
Signaling Pathway Determines Chemosensitivity of BMP4-Differentiated Glioma Stem Cells to Temozolomide

Scientists examined whether epidermal growth factor receptor (EGFR) signaling affected bone morphogenic protein 4-induced differentiation of glioma stem cells and their response to the alkylating drug temozolomide.
[Experimental and Molecular Medicine]

Full Article

Antagonists
of the Serotonin Receptor 5A Target Human Breast Tumor Initiating Cells

Researchers found that selective antagonists of 5-HT5A reduced the frequency of tumorsphere initiating cells residing in breast tumor cell lines and those of patient-derived xenografts that they established.
[BMC Cancer]

Full Article

Identification
of a Subpopulation of Long-Term Tumor-Initiating Cells in Colon Cancer

Based on the methods for isolating and identifying cancer stem cells and the functional features of long-term tumor-initiating cells (LT-TICs), the authors aimed to identify a subpopulation of LT-TICs.
[Bioscience Reports]

Abstract

Immunogenic
Cell Death of Breast Cancer Stem Cells by an Endoplasmic Reticulum‐Targeting Copper(II) Complex

Investigators report a copper(II) complex containing a Schiff base ligand and a polypyridyl ligand, 4 capable of inducing immunogenic cell death in breast cancer stem cells.
[Chembiochem]

Abstract

Apigenin
Enhanced Antitumor Effect of Cisplatin in Lung Cancer via Inhibition of Cancer Stem Cells

Scientists attempted to clarify whether apigenin could improve the antitumor efficiency of cisplatin in lung cancer using cancer stem cells.
[Nutrition and Cancer-An International Journal]

Abstract

Explore virtual support and resources to stay productive and connected with your field.

REVIEWS

Epithelial
Cell Adhesion Molecule: An Anchor to Isolate Clinically Relevant Circulating Tumor Cells

The authors summarize the most significant advantages and disadvantages of using epithelial cell adhesion molecule as a marker for circulating tumor cell enrichment and its potential biological role in the metastatic cascade.
[Cells]

Full Article

INDUSTRY AND POLICY NEWS

BryoLogyx
Announces Cooperative Research and Development Agreement for Bryostatin-1 with National Cancer Institute

BryoLogyx, Inc. announced that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute, to conduct a Phase I clinical trial with bryostatin-1 in pediatric and young adult patients with relapsing or refractory CD22 expressing acute lymphoblastic leukemia and lymphoma.
[BryoLogyx, Inc.]

Press Release

FEATURED EVENT

PAF1
Regulates Stem Cell Features of Pancreatic Cancer Cells, Independently of the PAF1 Complex, via Interactions with PHF5A and DDX3

Serial
Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy

LC3B
Upregulation by NANOG Promotes Immune Resistance and Stem-Like Property through Hyperactivation of EGFR Signaling in Immune-Refractory Tumor Cells

Broccoli
Extract Increases Drug-Mediated Cytotoxicity towards Cancer Stem Cells of Head and Neck Squamous Cell Carcinoma

EGFR/FOXO3a/BIM
Signaling Pathway Determines Chemosensitivity of BMP4-Differentiated Glioma Stem Cells to Temozolomide

Antagonists
of the Serotonin Receptor 5A Target Human Breast Tumor Initiating Cells

Identification
of a Subpopulation of Long-Term Tumor-Initiating Cells in Colon Cancer

Immunogenic
Cell Death of Breast Cancer Stem Cells by an Endoplasmic Reticulum‐Targeting Copper(II) Complex

Apigenin
Enhanced Antitumor Effect of Cisplatin in Lung Cancer via Inhibition of Cancer Stem Cells

Epithelial
Cell Adhesion Molecule: An Anchor to Isolate Clinically Relevant Circulating Tumor Cells

BryoLogyx
Announces Cooperative Research and Development Agreement for Bryostatin-1 with National Cancer Institute

Till & McCulloch Meetings 2020

> See All Events

Postdoctoral Associate – RNA Epigenetics in Cancer Stem Cells

Faculty Position – Prostate Cancer Biology and Cancer Epigenetics

Postdoctoral Fellowship – Hematopoiesis, Leukemia, and Bone Marrow Failure Syndromes

Postdoctoral Research Fellow – Hematopoiesis, Marrow Failure and Myeloid Leukemia

Postdoctoral
Positions – Cancer Epigenomics

> See All Jobs